Ask AI
Treating HR Pos HER2 Pos MBC

CME

Interactive Case Challenge: Treatment of HR-Positive/HER2-Positive Metastatic Breast Cancer

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

European Learners: 0.50 EBAC® CE Credit

Released: February 03, 2026

Expiration: August 02, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

For a patient with hormone receptor (HR)–positive/HER2-positive metastatic breast cancer (MBC) who has a had a good response to first-line trastuzumab/pertuzumab/taxane (THP), a switch to maintenance therapy with which of the following agents added to trastuzumab plus pertuzumab and endocrine therapy (ET) significantly improved PFS compared with trastuzumab plus pertuzumab and ET in a phase III study?